Pathology of True Malignant Mixed Tumor (Carcinosarcoma)

Updated: Dec 01, 2015

Author: M Sherif Said, MD, PhD; Chief Editor: M Sherif Said, MD, PhD

Definition

Different patterns of malignant change occur in pleomorphic adenoma, of which true malignant mixed tumor (carcinosarcoma) is one form. The other 2 forms are carcinoma ex pleomorphic adenoma and metastasizing benign pleomorphic adenoma.

By definition, carcinosarcoma is a biphasic malignant tumor with a carcinomatous component and a sarcomatous component. Most of these tumors arise in the background of pleomorphic adenoma; however, some arise de novo .

Carcinosarcoma of the salivary glands was first described by Kirklin et al in 1951.[1] The term true malignant mixed tumor in the salivary glands was first used by King in 1967 in a study that helped to renew interest in this tumor group.[2]

Epidemiology

Carcinosarcoma is an extremely rare and aggressive entity.[3] It accounts for only 0.04-0.16% of all salivary gland tumors. In the reported cases, patients ranged in age from 15-85 years. There was no predilection with regard to gender. Many of the patients had a history of pleomorphic adenoma, recurrent pleomorphic adenoma, or recurrent carcinoma ex pleomorphic adenoma.[3, 4, 5, 6, 7, 8, 9, 10, 11, 12] Some cases, however, seem to arise de novo, in the absence of a previous pleomorphic adenoma.[3, 13, 14, 15, 16]

Etiology

No clear etiology is known. However, accumulation of genetic mutations could be a factor. A history of exposure to irradiation of pleomorphic adenoma has been reported.[11, 17] The reported interval between the irradiation and the onset of carcinosarcoma varies from 1 to 36 years.

Two schools of thought exist as to the origin of carcinosarcomas. The convergence hypothesis maintains that multiclonal stem cells of the epithelial and mesenchymal components play a causative role. The divergence hypothesis postulates a monoclonal origin from a single totipotent stem cell with divergent differentiation.[18, 19] The latter hypothesis is more favored.

Gotte et al hypothesized that the tumor originates from a myoepithelial cell precursor.[20] Other investigators have postulated that the tumor originates from inner ductal cells[5] or a pluripotent primitive cell.[14]

Location

In the major salivary glands, most reported cases of carcinosarcoma (65%) occurred in the parotid gland.[1, 3, 4] Some cases (19%) have been reported in the submandibular gland.[3, 14, 21] In the minor salivary glands, the palate is the most common site,[6] but other sites, including the cheek, have been reported.[22, 23]

Clinical Features and Imaging

The tumor presents as a mass that may be rapidly enlarging.[24] In some cases, the mass is painful; the pain may be localized, referred, or both. If the parotid gland is involved, signs of facial nerve weakness/paralysis are commonly encountered.

Gross Findings

True malignant mixed tumors are poorly circumscribed, with infiltrative borders. They are gray, and focal areas of hemorrhage and necrosis may be present. Some tumors are well circumscribed. Most reported tumors range from 2-13 cm in greatest dimension.

Microscopic Findings

A carcinosarcoma neoplasm is a biphasic tumor in which the carcinomatous component is usually a poorly differentiated adenocarcinoma, an undifferentiated carcinoma, or a squamous cell.[25] It may also include adenoid cystic carcinoma, epithelial myoepithelial carcinoma, and salivary duct carcinoma.

The sarcomatous component is usually a chondrosarcoma. Other reported sarcomatous elements include spindle cell sarcoma not otherwise specified (NOS), fibrosarcoma, osteosarcoma, leiomyosarcoma, liposarcoma, follicular dendritic cell sarcoma, undifferentiated sarcoma, myxoid sarcomas, and rhabdomyosarcoma,[26, 16] among others. The relative proportion of the 2 components is variable, and either component may dominate the histologic picture.

In the images below, the sarcomatous (spindle cell sarcoma) component of the tumor is dominant, with the smaller portion being poorly differentiated adenocarcinoma.

The carcinomatous component of a carcinosarcoma of the parotid gland. In this case, the tumor is a poorly differentiated adenocarcinoma.

The sarcomatous component of a carcinosarcoma of the parotid gland. In this case, the tumor is a spindle cell sarcoma not otherwise specified (NOS).

The histologic picture depends on the types of the constituent cells of sarcoma and carcinoma. Extensive infiltration and tissue destruction are common, as are perineural invasion and angioinvasion. Lymphatic spread is less common.[27]

Metastases to other sites or lymph nodes may show the carcinomatous or the sarcomatous components alone, or the components may be mixed.

Immunohistochemistry

The immunohistochemical panel varies, depending on the observed biphasic components of the tumor. Generally speaking, however, the carcinomatous component is usually positive for cytokeratin and epithelial membrane antigen (EMA). However, it should be noted that in very poorly differentiated tumors, the carcinomatous component may show only focal or weak positive staining for cytokeratins or EMA, a feature that is sometimes encountered in very poorly differentiated cancers of the head and neck. In such cases, electron microscopy may be helpful. The sarcomatous component is vimentin positive.

Molecular/Genetics

Few genetic studies have been performed on these tumors, owing to their rarity. However, abnormalities in chromosomes 7, 8, 9, 10, 12, 13, 17, and 18 have been described.[19, 20] A study showed specific amplifications of mucin 20 (MUC 20) in mesenchymal elements (gene products that are known to be overexpressed in various cancers and that correlate with poor outcome). BMI-1 (a proto-oncogene found to be deregulated in several neoplasms, including salivary gland tumors) was observed in both element loci.[19]

Tumor Spread and Staging

Tumor spread may occur by direct extension, hematogenous, lymphatic, or perineural invasion.

Tumor staging in the salivary glands depends on whether the tumor is located in the head or neck area. Tables 1 and 2 define the American Joint Committee on Cancer (AJCC) staging of malignant tumors of the major salivary glands (ie, parotid, submandibular, sublingual).[28]

Table 1. TNM Classification (Open Table in a new window)

T-	Primary Tumor
Tx	Primary tumor cannot be assessed
T0	No evidence of primary tumor
T1	Tumor 2cm or less in greatest dimension, without extraparenchymal extension
T2	Tumor more than 2cm, but not more than 4cm, in greatest dimension, without extraparenchymal extension
T3	Tumor more than 4cm and/or tumor having extraparenchymal extension
T4a	Tumor invades skin, mandible, ear canal, and/or facial nerve
T4b	Tumor invades skull base and/or pterygoid plates and/or carotid artery
N-	Regional Lymph Nodes
NX	Regional lymph nodes cannot be assessed
N0	No regional lymph node metastasis
N1	Metastasis into a single ipsilateral lymph node, 3cm or less in greatest dimension
N2	Metastasis into a single ipsilateral lymph node, greater than 3cm in greatest dimension but not greater than 6cm in greatest dimension, or in multiple ipsilateral lymph nodes, none greater than 6cm in greatest dimension, or in bilateral or contralateral lymph nodes, none greater than 6cm in greatest dimension
N3	Metastasis in a lymph node greater than 6cm in greatest dimension
M-	Distant metastasis
MX	Distant metastasis cannot be assessed
M0	No distant metastasis
M1	Distant metastasis

Table 2. Stage Grouping (Open Table in a new window)

Stage	Grouping
Stage I	T1 N0 M0
Stage II	T2 N0 M0
Stage III	T3 N0 M0
	T1 N1 M0
	T2 N1 M0
	T3 N1 M0
Stage IVA	T4a N0 M0
	T4a N1 M0
	T1 N2 M0
	T2 N2 M0
	T3 N2 M0
	T4a N2 M0
Stage IVB	T4b Any N M0
	Any T N3 M0
Stage IVC	Any T Any N M1

Prognosis and Predictive Factors

Carcinosarcoma is an aggressive, high-grade tumor. Recurrence, distant metastasis (54%), and angiolymphatic invasion are frequently encountered. The lungs are the most common site of metastasis. Metastasis may also occur to the liver, bones, and brain. Involvement of cervical lymph nodes with metastasis is uncommon.

In a review by Gnepp,[3] 58% of patients died as a result of the tumor. A review of 19 cases of de novo carcinosarcomas by Staffeieri et al[16] found that 31.6% of patients died of the disease. The median period of survival after diagnosis was 10 months; in 63% of cases, there was no evidence of recurrence after a median period of 22.4 months.

Because of the rarity of the tumor, whether arising de novo or in a pleomorphic adenoma, consensus on therapeutic approaches has been lacking. A combination of surgery followed by radiotherapy seems to be statistically superior to resection alone.[16, 29] The role of chemotherapy remains unclear.

The results of a retrospective analysis of 15 cases of sinonasal carcinosarcoma suggested that patients with sinonasal carcinosarcoma have disease-specific survival comparable to the case-matched cohort of salivary gland carcinosarcoma patients. The study added that sinonasal carcinosarcoma patients have significantly poor survival outcomes compared to patients from the cohort of carcinosarcoma at all other head and neck sites.[30]

Questions & Answers

Overview

How is true malignant mixed tumor (carcinosarcoma) defined?

What is the prevalence of true malignant mixed tumor (carcinosarcoma)?

What causes true malignant mixed tumor (carcinosarcoma)?

Where is true malignant mixed tumor (carcinosarcoma) located?

What are the signs and symptoms of true malignant mixed tumor (carcinosarcoma)?

Which gross findings are characteristic of true malignant mixed tumor (carcinosarcoma)?

Which histologic findings are characteristic of true malignant mixed tumor (carcinosarcoma)?

Which immunohistochemical findings are characteristic of true malignant mixed tumor (carcinosarcoma)?

Which cytogenetic findings are characteristic of true malignant mixed tumor (carcinosarcoma)?

How are true malignant mixed tumors (carcinosarcomas) staged?

What is the prognosis of true malignant mixed tumor (carcinosarcoma)?

Kirklin JW, McDonald JR, Harrington SW, New GB. Parotid tumors; histopathology, clinical behavior, and end results. Surg Gynecol Obstet. 1951 Jun. 92(6):721-33. [QxMD MEDLINE Link].
King OH Jr. Carcinosarcoma of accessory salivary gland. First report of a case. Oral Surg Oral Med Oral Pathol. 1967 May. 23(5):651-9. [QxMD MEDLINE Link].
Gnepp DR. Malignant mixed tumors of the salivary glands: a review. Pathol Annu. 1993. 28 Pt 1:279-328. [QxMD MEDLINE Link].
Stephen J, Batsakis JG, Luna MA, von der Heyden U, Byers RM. True malignant mixed tumors (carcinosarcoma) of salivary glands. Oral Surg Oral Med Oral Pathol. 1986 Jun. 61(6):597-602. [QxMD MEDLINE Link].
Alvarez-Cañas C, Rodilla IG. True malignant mixed tumor (carcinosarcoma) of the parotid gland. Report of a case with immunohistochemical study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1996 Apr. 81(4):454-8. [QxMD MEDLINE Link].
Carson HJ, Tojo DP, Chow JM, Hammadeh R, Raslan WF. Carcinosarcoma of salivary glands with unusual stromal components. Report of two cases and review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1995 Jun. 79(6):738-46. [QxMD MEDLINE Link].
Gandour-Edwards RF, Donald PJ, Vogt PJ, Munn R, Min KW. Carcinosarcoma (malignant mixed tumor) of the parotid: report of a case with a pure rhabdomyosarcoma component. Head Neck. 1994 Jul-Aug. 16(4):379-82. [QxMD MEDLINE Link].
Granger JK, Houn HY. Malignant mixed tumor (carcinosarcoma) of parotid gland diagnosed by fine-needle aspiration biopsy. Diagn Cytopathol. 1991. 7(4):427-32. [QxMD MEDLINE Link].
Hellquist H, Michaels L. Malignant mixed tumour. A salivary gland tumour showing both carcinomatous and sarcomatous features. Virchows Arch A Pathol Anat Histopathol. 1986. 409(1):93-103. [QxMD MEDLINE Link].
López JI, Ballestin C, Garcia-Prats MD, De Agustin P. Carcinosarcoma of the parotid gland: immunohistochemical study of a case. Histopathology. 1994 Oct. 25(4):388-90. [QxMD MEDLINE Link].
Spraggs PD, Rose DS, Grant HR, Gallimore AP. Post-irradiation carcinosarcoma of the parotid gland. J Laryngol Otol. 1994 May. 108(5):443-5. [QxMD MEDLINE Link].
Thamilselvi R, Subramaniam PM, Shivarudrappa AS, et al. Sarcomatoid salivary duct carcinoma of minor salivary gland: a rare case. Indian J Pathol Microbiol. 2010 Oct-Dec. 53(4):808-10. [QxMD MEDLINE Link].
Latkovich P, Johnson RL. Carcinosarcoma of the parotid gland: report of a case with cytohistologic and immunohistochemical findings. Arch Pathol Lab Med. 1998 Aug. 122(8):743-6. [QxMD MEDLINE Link].
Bleiweiss IJ, Huvos AG, Lara J, Strong EW. Carcinosarcoma of the submandibular salivary gland. Immunohistochemical findings. Cancer. 1992 Apr 15. 69(8):2031-5. [QxMD MEDLINE Link].
Grenko RT, Tytor M, Boeryd B. Giant-cell tumour of the salivary gland with associated carcinosarcoma. Histopathology. 1993 Dec. 23(6):594-5. [QxMD MEDLINE Link].
Staffieri C, Marioni G, Ferraro SM, Marino F, Staffieri A. Carcinosarcoma de novo of the parotid gland. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007 Aug. 104(2):e35-40. [QxMD MEDLINE Link].
Hellquist H, Michaels L. Malignant mixed tumour. A salivary gland tumour showing both carcinomatous and sarcomatous features. Virchows Arch A Pathol Anat Histopathol. 1986. 409(1):93-103. [QxMD MEDLINE Link].
Thompson L, Chang B, Barsky SH. Monoclonal origins of malignant mixed tumors (carcinosarcomas). Evidence for a divergent histogenesis. Am J Surg Pathol. 1996 Mar. 20(3):277-85. [QxMD MEDLINE Link].
Vékony H, Leemans CR, Ylstra B, Meijer GA, van der Waal I, Bloemena E. Salivary gland carcinosarcoma: oligonucleotide array CGH reveals similar genomic profiles in epithelial and mesenchymal components. Oral Oncol. 2009 Mar. 45(3):259-65. [QxMD MEDLINE Link].
Götte K, Riedel F, Coy JF, Spahn V, Hörmann K. Salivary gland carcinosarcoma: immunohistochemical, molecular genetic and electron microscopic findings. Oral Oncol. 2000 Jul. 36(4):360-4. [QxMD MEDLINE Link].
Bhalla RK, Jones TM, Taylor W, Roland NJ. Carcinosarcoma (malignant mixed tumor) of the submandibular gland: A case report and review of the literature. J Oral Maxillofac Surg. 2002 Sep. 60(9):1067-9. [QxMD MEDLINE Link].
Sharma A, Deshmukh S, Shaikh A, Dabholkar J. Pleomorphic adenoma of the minor salivary gland of the cheek. Singapore Med J. 2013 Sep. 54(9):e183-4. [QxMD MEDLINE Link].
Bovino BF, Sohn A, Winston D. Pleomorphic adenoma of the palate in a child. N Y State Dent J. 2013 Jun-Jul. 79(4):44-7. [QxMD MEDLINE Link].
Kato H, Kanematsu M, Mizuta K, Aoki M. Imaging findings of parapharyngeal space pleomorphic adenoma in comparison with parotid gland pleomorphic adenoma. Jpn J Radiol. 2013 Aug 30. [QxMD MEDLINE Link].
Mitate E, Kawano S, Kiyoshima T, Kawazu T, Chikui T, Goto Y, et al. Carcinoma ex pleomorphic adenoma of the upper lip: a case of an unusual malignant component of squamous cell carcinoma. World J Surg Oncol. 2013 Sep 17. 11(1):234. [QxMD MEDLINE Link].
Kwon MY, Gu M. True malignant mixed tumor (carcinosarcoma) of parotid gland with unusual mesenchymal component: a case report and review of the literature. Arch Pathol Lab Med. 2001 Jun. 125(6):812-5. [QxMD MEDLINE Link].
Qureshi A, Barakzai A, Sahar NU, Gulzar R, Ahmad Z, Hassan SH. Spectrum of malignancy in mixed tumors of salivary gland: a morphological and immunohistochemical review of 23 cases. Indian J Pathol Microbiol. 2009 Apr-Jun. 52(2):150-4. [QxMD MEDLINE Link].
American Joint Committee on Cancer. Major salivary glands. Greene FL, Page DL, Fleming ID, Fritz AG, Balch CM, Haller DG, et al, eds. AJCC Cancer Staging Manual. 6th ed. New York: Springer-Verlag; 2002. 69-75.
Alterio D, Jereczek-Fossa BA, Griseri M, et al. Three-dimensional conformal postoperative radiotherapy in patients with parotid tumors: 10 years' experience at the European Institute of Oncology. Tumori. 2011 May-Jun. 97(3):328-34. [QxMD MEDLINE Link].
Patel TD, Vázquez A, Plitt MA, Baredes S, Eloy JA. A case-control analysis of survival outcomes in sinonasal carcinosarcoma. Am J Otolaryngol. 2015 Mar-Apr. 36 (2):200-4. [QxMD MEDLINE Link].